Effects of prazosin and alphamethyldopa on blood lipids and lipoproteins in hypertensive patients.
The effects of prazosin and alphamethyldopa on blood lipids and lipoproteins were assessed in 20 patients with mild or moderate arterial hypertension. Parameters measured included serum cholesterol (CHO), triglycerides (TG), high density lipoprotein-cholesterol (HDL-CHO), insulin (I), glucose (G), and non-esterified fatty acids (NEFA). Prazosin -4 mg/day for 6 weeks in hydrochlorothiazide-treated patients lowered blood pressure by 18.6/17.2 (systolic/diastolic pressure) mmHg. There was a significant decrease in CHO (-5.8%), in I (-16.5%), and in NEFA (-3.0%), and a significant increase in HDL-CHO (+15.5%). Alphamethyldopa 250-750 mg/day for 6 weeks in hydrochlorothiazide-treated patients lowered blood pressure by 18.8/14.6 (systolic/diastolic pressure) mmHg, accompanied by a non-significant decrease in CHO and TG, and significant increases in HDL-CHO (+10.3%), G (+8.5%) and NEFA (+6.4%). Thus, prazosin appears to have a more beneficial effect on blood lipids and lipoproteins than alphamethyldopa.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008750:Methyldopa / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D011224:Prazosin / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation
D005230:Fatty Acids, Nonesterified; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D008750:Methyldopa; D011224:Prazosin